Dual Blockade of EGFR Tyrosine Kinase Using Osimertinib and Afatinib Eradicates EGFR‑mutant Ba/F3 Cells
Oncology Reports - Greece
doi 10.3892/or.2018.6881
Full Text
Open PDFAbstract
Available in full text
Date
November 22, 2018
Authors
Publisher
Spandidos Publications